ReviewJournal of diabetes and metabolic disorders2025
Fetuin-A levels in diabetic retinopathy: a systematic review and meta-analysis.
Review in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bacopa monniera: A Promising Phytotherapeutic Approach in Management of Diabetes-Related Complications.Phytotherapy research : PTR · 2026Review
- Review
- The evolving roles of fetuin-A in type 2 diabetes mellitus and its potential clinical implications: a review.Therapeutic advances in chronic disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic retinopathy (DR) is one of the main microvascular complications of diabetes and one of the most common causes of vision loss worldwide. Fetuin-A is a glycoprotein correlated with insulin resistance and has been measured in DR patients. Herein, we aimed to investigate these studies through a systematic review and meta-analysis. Methods: Four online databases, including PubMed, Embase, Scopus, and the Web of Science were searched comprehensively in order to retrieve relevant studies that compared blood fetuin-A levels in patients with DR vs. non-DR, DR vs. non-diabetic controls, non-DR vs. non-diabetic controls, and proliferative vs. non- proliferative DR. Random-effect meta-analysis was performed for the calculation of the standardized mean difference (SMD) and 95% confidence interval (CI). Results: From the 186 found results through database search, after eligibility assessment, seven studies were included. A total of 1104 cases with a mean age of 57.24 ± 9.62 years were investigated. Meta-analysis showed that fetuin-A levels were significantly higher in patients with DR compared to both non-DR diabetic patients (SMD 0.41, 95% CI 0.10 to 0.72, Conclusion: Based on our findings, fetuin-A was higher in patients with DR and could be potentially used for measurement in clinical settings if confirmed in future large-scale studies. Moreover, the fact that higher fetuin-A levels were associated with proliferative DR could have clinical implications. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-024-01533-0.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.